Dr. Black on Biomarkers for Immunotherapy in Bladder Cancer

Peter Black, MD
Published: Wednesday, Aug 09, 2017



Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses biomarker development in bladder cancer.

Since only 20% to 25% of patients have an objective response, developing biomarkers is important to determine which treatments a patient should receive, explains Black. PD-L1 is a current biomarker in development, but currently has no utility in bladder cancer, states Black. Additionally, peripheral immune cells and sequencing T-cell receptors are also in development.
 


Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses biomarker development in bladder cancer.

Since only 20% to 25% of patients have an objective response, developing biomarkers is important to determine which treatments a patient should receive, explains Black. PD-L1 is a current biomarker in development, but currently has no utility in bladder cancer, states Black. Additionally, peripheral immune cells and sequencing T-cell receptors are also in development.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x